Clinical Trial Search

Primary: Percentage of Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine…

Primary: Self Reported Relapse Rate at 2 Months — 3; 10; 13 participants — p=0.033

Primary: Rates of Safety Outcomes at Days 0-30 vs Days 31-75 After Menactra Vaccine - Emergency Room Database. — 0.009; 0.006; 0.009; 0.006 Events per 1,000 person-months

Primary: Number of Bleeding Sites at Week 12 — 42.02; 67.36 number of bleeding sites — p=<0.0001

Primary: Percentage of Participants Who Were Treatment Failures. — 21.3; 45.5 percentage of treatment failures

Primary: Safety and Toxicity as Measured by Treatment Related Non-hematologic Adverse Events — 34; 6; 7; 3 participants

Primary: Therapy Session Satisfaction (as Measured by Subjective Report) — 9.8; 9.7 units on a scale

Primary: Comparing Laparoscopic-assisted Resection to Open Rectal Resection for Rectal Cancer as Measured by the Percentage of Patients With Successful Resection Based on…

Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 — 73.2; 65.5; 76.8; 81.8 percentage of participants — p==0.863

Primary: Rate of Device and/or Procedure-related Adverse Events — 42.5 percentage of participants

Primary: Primary: Participants With EULAR (Good) — 19 participants

Primary: Number of Participants With Objective Response — 3; 1; 1; 7 Participants

Primary: Progression Free Survival (PFS) — 12.9; 18.5 Months

Primary: Number of Patients With Adverse Events, Serious Adverse Events, and Death — 16; 94; 0 Participants

Primary: Hair Density Change After Three Treatments — 175.1 percentage of pre-treatment hair density